Testicular Cancer

Testicular cancer is the most common malignancy in males aged 15 to 35 and one of the most curable solid tumors in oncology. Approximately 95% of cases arise from germ cells — the spermatogonial stem cells of the seminiferous tubules. Despite its relative rarity (about 9,000 new cases annually in the United States), testicular cancer commands outsized clinical importance because it represents a proof-of-concept for curative chemotherapy: even widely metastatic disease is routinely cured with cisplatin-based regimens. Understanding tumor subtypes, the role of serum tumor markers, and risk stratification systems is essential for both patients and clinicians navigating this diagnosis.

Table of Contents

1. Overview and Epidemiology
2. Tumor Subtypes and Pathology
3. Risk Factors
4. Clinical Presentation
5. Tumor Markers
6. Diagnosis and Staging
7. IGCCCG Prognosis Groups
8. Treatment by Stage
9. Survivorship and Late Effects
10. Recent Research
11. Key Research Papers
12. PubMed Topic Searches
13. Connections
14. Featured Videos

1. Overview and Epidemiology

Testicular cancer accounts for roughly 1% of all male malignancies but represents approximately 15% of cancers diagnosed in men aged 15–35, making it the most common solid tumor in young adult males. Incidence has doubled in Western countries over the past five decades — a trend not fully explained by improved detection — with the highest rates in Scandinavia, Germany, New Zealand, and North America among White populations. In the United States, approximately 9,400 new cases and 440 deaths are expected annually, reflecting a cure rate exceeding 95% overall.

The age distribution is bimodal: germ cell tumors peak in the third and fourth decades, while non-germ cell tumors (Leydig cell, Sertoli cell) and lymphoma have a distinct elderly-male peak. Seminoma tends to present about a decade later (peak age 30–40) compared to non-seminomatous germ cell tumors (NSGCTs, peak age 20–30).

Racial disparities are striking: incidence is approximately four times higher in White males than in Black males in the United States, though Black patients with testicular cancer historically had worse outcomes, likely due to later-stage diagnosis and access barriers.

Back to Table of Contents

2. Tumor Subtypes and Pathology

Approximately 95% of testicular tumors are germ cell tumors (GCTs), arising from primordial germ cells of the testis. The remaining 5% includes stromal tumors (Leydig cell, Sertoli cell), lymphoma, metastatic deposits, and rare entities.

Germ Cell Tumors

All invasive GCTs in adults share a common precursor lesion: germ cell neoplasia in situ (GCNIS), formerly called intratubular germ cell neoplasia (ITGCN). GCNIS is detectable by testicular biopsy and is found in up to 5% of the contralateral testis in men with testicular GCT. The hallmark molecular aberration shared by virtually all GCTs is isochromosome 12p (i12p) — an isochromosome formed by duplication of the short arm of chromosome 12. Gain of 12p material drives overexpression of cyclins D2 and CCND2, promoting uncontrolled germ cell proliferation. Detection of i12p in a tumor of unknown primary strongly supports a germ cell origin.

• Seminoma (approximately 50% of GCTs): Sheets of uniform large cells with clear cytoplasm and prominent nucleoli, classically associated with a lymphocytic stromal infiltrate. Seminomas are radiosensitive. Critically, seminoma never elevates alpha-fetoprotein (AFP) — any AFP elevation in a tumor classified histologically as seminoma mandates reclassification as a mixed GCT. Beta-human chorionic gonadotropin (βhCG) is elevated in 10–20% of seminomas due to synctiotrophoblastic giant cells.
• Non-Seminomatous GCTs (NSGCTs): A heterogeneous group that may occur as pure histologies or as mixed tumors combining multiple elements. The four NSGCT subtypes are:
  • Embryonal carcinoma: The most common NSGCT element; high-grade primitive cells resembling embryonic disc; characteristically elevates LDH and occasionally βhCG; aggressive with vascular invasion.
  • Yolk sac tumor (endodermal sinus tumor): Recapitulates yolk sac structures; the dominant histology in prepubertal boys; produces AFP; Schiller-Duval bodies are pathognomonic.
  • Choriocarcinoma: Recapitulates placental trophoblast; cytotrophoblasts + synctiotrophoblasts; dramatically elevated βhCG (can mimic pregnancy or cause gynecomastia); most aggressive subtype; hematogenous spread to lung, liver, brain.
  • Teratoma: Differentiated somatic tissue from two or more germ layers; in adults, not benign — has malignant potential and is chemoresistant. Mature teratoma is the dominant residual mass after chemotherapy; growing teratoma syndrome (retroperitoneal expansion despite declining markers) requires surgical resection.
• Mixed GCTs: The majority of NSGCTs contain more than one histologic component; mixed tumors are managed as NSGCTs regardless of the proportion of seminoma.

Back to Table of Contents

3. Risk Factors

Despite considerable research, the etiology of testicular GCT remains incompletely understood. The most established risk factors are:

• Cryptorchidism (undescended testis): The strongest modifiable risk factor; associated with a 4- to 8-fold increased relative risk. Orchiopexy (surgical correction) before puberty reduces but does not eliminate the risk, and the contralateral normally descended testis also carries modestly elevated risk. Approximately 10% of men with testicular GCT have a history of cryptorchidism.
• Personal history of GCT: Men with a prior GCT in one testis carry approximately 12 times the general population risk for a contralateral tumor; cumulative contralateral risk is approximately 2–5% at 15 years.
• Family history: Brothers of affected men have 6- to 10-fold elevated risk; fathers and sons approximately 4-fold elevated risk, suggesting polygenic susceptibility loci. Genome-wide association studies have identified multiple common susceptibility alleles near genes including KITLG, SPRY4, ATF7IP, and BAK1.
• Testicular dysgenesis syndrome: The testicular dysgenesis hypothesis proposes a common etiologic pathway linking cryptorchidism, hypospadias, impaired spermatogenesis, and testicular GCT — all manifestations of disrupted gonadal development, potentially triggered by prenatal endocrine-disrupting exposures.
• Klinefelter syndrome (47,XXY): Substantially increased risk of mediastinal (but not testicular) GCT, particularly mediastinal seminoma.
• Infertility and testicular atrophy: Independently associated with elevated GCT risk, supporting a shared gonadal dysgenesis pathway.
• HIV infection: Significantly elevated risk of seminoma in HIV-positive men, likely related to immune dysregulation rather than antiretroviral exposure.

Back to Table of Contents

4. Clinical Presentation

The classic presentation is a painless, firm, unilateral testicular mass or diffuse testicular enlargement discovered incidentally by the patient or a sexual partner. Key features:

• Painless mass: Present in approximately 70–80% of cases; the absence of pain often leads to diagnostic delay of 3–6 months as patients and primary care physicians mistake the finding for epididymo-orchitis or trauma.
• Orchalgia (testicular pain or heaviness): Present in approximately 30–40% of men; dull aching or heaviness rather than acute pain; can mislead toward epididymitis or torsion diagnoses.
• Gynecomastia: Present in 5–10% of patients, most commonly with choriocarcinoma (due to massive βhCG elevation) or Leydig cell tumors (estrogen excess). May be the presenting complaint before the testicular mass is detected.
• Back pain or flank pain: Suggests retroperitoneal lymphadenopathy (bulky nodal metastases); can be the presenting symptom in advanced disease when the primary tumor is small.
• Dyspnea, hemoptysis, or cough: Pulmonary metastases; predominantly in embryonal carcinoma and choriocarcinoma.
• Headache or neurologic symptoms: Brain metastases occur in 10–15% of poor-risk GCTs, particularly choriocarcinoma; CNS metastases may present with headache, seizures, or focal neurologic deficits.
• Elevated βhCG and hyperthyroidism: βhCG shares alpha-subunit homology with TSH; in choriocarcinoma with massive βhCG elevation, clinically significant hyperthyroidism can develop.

Physical examination includes careful palpation of both testes (to assess contralateral involvement), assessment for gynecomastia, and examination of lymph node chains. Testicular GCT drains to retroperitoneal lymph nodes (not inguinal), so inguinal lymphadenopathy is absent unless there is prior scrotal violation or scrotal skin involvement.

Back to Table of Contents

5. Tumor Markers

Serum tumor markers are central to testicular cancer management — not merely for diagnosis but critically for staging, treatment monitoring, and recurrence surveillance. Markers must be measured before orchiectomy (to establish preoperative baseline) and serially after resection (to confirm appropriate half-life decline, which distinguishes complete resection from residual or micrometastatic disease).

• Alpha-fetoprotein (AFP):
  • Produced by yolk sac tumor elements; never produced by pure seminoma or pure choriocarcinoma.
  • Half-life: 5–7 days. A decline following orchiectomy slower than predicted by half-life kinetics implies residual disease even if the absolute value is falling toward normal.
  • Upper limit of normal: approximately 10 ng/mL (lab-dependent). IGCCCG poor-risk threshold: AFP >10,000 ng/mL.
  • Persistent AFP elevation after orchiectomy requires systemic therapy regardless of CT findings.
• Beta-human chorionic gonadotropin (βhCG):
  • Produced by syncytiotrophoblastic giant cells; elevated in virtually all choriocarcinomas, approximately 40–60% of NSGCTs, and 10–20% of seminomas.
  • Half-life: 24–36 hours. Rapid decline expected post-orchiectomy.
  • Very high βhCG levels (>50,000 IU/L) suggest choriocarcinoma or widespread NSGCT and correlate with poor prognosis.
  • Mild βhCG elevation in men with hypogonadism or marijuana use can be a confounder.
• Lactate dehydrogenase (LDH):
  • Non-specific marker of tumor cell turnover and bulk; used primarily in the IGCCCG staging system and in monitoring response in high-burden disease.
  • Elevated in approximately 60% of GCTs overall; poor prognostic marker when markedly elevated (>10× ULN in IGCCCG poor-risk definition).
  • LDH is routinely checked but not specific enough to guide therapy alone.
• Placental alkaline phosphatase (PLAP): A marker for seminoma; less routinely used in North American practice but informative in marker-negative seminoma cases.

Back to Table of Contents

6. Diagnosis and Staging

Initial Evaluation

Testicular ultrasound is the first-line imaging modality for any suspicious testicular mass, with sensitivity approaching 100% for intratesticular lesions. A hypoechoic, heterogeneous intratesticular mass is highly suspicious for malignancy. Ultrasound distinguishes intratesticular from extratesticular masses and can identify microlithiasis (associated with GCNIS/GCT risk). Inguinal, never trans-scrotal, biopsy or orchiectomy — violating the scrotal skin disrupts lymphatic drainage and may upstage disease to inguinal nodes.

Radical Inguinal Orchiectomy

Radical inguinal orchiectomy is both the diagnostic procedure and the primary therapeutic intervention. The testicle is removed via an inguinal incision with high ligation of the spermatic cord at the internal inguinal ring. Pathologic examination defines histology, establishes the presence or absence of vascular/lymphatic invasion (a key staging element), and provides material for tumor marker reassessment. Tumor markers are drawn immediately before and serially after orchiectomy.

Staging Workup

• CT chest/abdomen/pelvis with contrast: Mandatory for all patients. Assesses retroperitoneal lymph nodes (primary drainage basin), mediastinal and hilar nodes, and pulmonary parenchyma. Standard nodal size threshold for N1 is ≥10 mm short axis.
• MRI brain: Obtained for all poor-risk patients and any patient with neurologic symptoms; choriocarcinoma warrants brain MRI regardless of symptoms given high rate of CNS metastasis.
• PET-CT: Not routinely used at diagnosis; valuable in seminoma post-chemotherapy to evaluate residual masses ≥3 cm (FDG-avidity predicts viable seminoma vs necrosis/fibrosis).

Staging (AJCC 8th Edition)

Testicular cancer staging integrates pathologic tumor extent (pT), nodal status (N), distant metastases (M), and critically, serum tumor marker levels at their nadir post-orchiectomy (S):

• Stage I: Tumor confined to testis; no nodal or distant disease; markers normalizing per expected kinetics.
• Stage II: Retroperitoneal lymph node involvement (IIA: ≤2 cm; IIB: 2–5 cm; IIC: >5 cm); no distant metastases.
• Stage III: Supradiaphragmatic nodal involvement or distant metastases (IIIA–IIIC based on marker levels and sites).

Back to Table of Contents

7. IGCCCG Prognosis Groups

The International Germ Cell Cancer Collaborative Group (IGCCCG) classification system, derived from a multinational dataset of over 5,000 patients and validated in subsequent cohorts, stratifies men with metastatic GCT into three prognostic groups based on histology, primary site, AFP/βhCG/LDH levels, and presence of non-pulmonary visceral metastases. These groups drive intensity and duration of chemotherapy.

Seminoma

• Good risk: Any primary site + no non-pulmonary visceral metastases + normal AFP + any βhCG + any LDH. 5-year OS: approximately 86%.
• Intermediate risk: Any primary site + non-pulmonary visceral metastases (liver, bone, brain) + normal AFP + any βhCG + any LDH. 5-year OS: approximately 72%.
• No poor-risk category for seminoma.

Non-Seminoma

• Good risk: Testicular/retroperitoneal primary + no non-pulmonary visceral metastases + AFP <1,000 ng/mL + βhCG <5,000 IU/L + LDH <1.5× ULN. 5-year OS: approximately 92%.
• Intermediate risk: Testicular/retroperitoneal primary + no non-pulmonary visceral metastases + AFP 1,000–10,000 ng/mL or βhCG 5,000–50,000 IU/L or LDH 1.5–10× ULN. 5-year OS: approximately 80%.
• Poor risk: Mediastinal primary OR non-pulmonary visceral metastases (liver, bone, CNS) OR AFP >10,000 ng/mL OR βhCG >50,000 IU/L OR LDH >10× ULN. 5-year OS: approximately 48–56% historically; improving with intensified regimens in trials.

Back to Table of Contents

8. Treatment by Stage

Stage I Seminoma

After radical inguinal orchiectomy, three management options exist:

• Active surveillance (preferred for most patients): CT imaging and tumor markers on a defined schedule (most intensive in years 1–2). Approximately 15–20% of stage I seminoma patients relapse, nearly always in the retroperitoneum, and are curable with salvage chemotherapy. Avoids overtreatment of the 80–85% who would never relapse.
• Adjuvant single-dose carboplatin (AUC 7): Reduces relapse rate by approximately 50% compared to surveillance; non-inferior to adjuvant radiation in relapse rate and OS with fewer long-term toxicities. Preferred over radiation in most contemporary guidelines.
• Adjuvant retroperitoneal radiotherapy (20 Gy, dog-leg field): Reduces relapse rate to <5%; historical standard but now less favored due to secondary malignancy risk (contralateral testicular cancer, stomach cancer, bladder cancer) from scattered radiation.

Stage I NSGCT

• Surveillance (preferred for low-risk stage I NSGCT): Risk of occult metastasis approximately 20–30% overall; recurrence rates on surveillance reflect true stage I proportion. Compliance with imaging schedule is essential — the recurrence window extends to 5 years with late relapses rare but documented.
• One cycle of BEP (bleomycin + etoposide + cisplatin): Reduces relapse rate to approximately 3–5% in high-risk stage I NSGCT (lymphovascular invasion present in primary tumor). A single cycle minimizes cumulative cisplatin and bleomycin toxicities while providing meaningful risk reduction.
• Retroperitoneal lymph node dissection (RPLND): Nerve-sparing primary RPLND for clinical stage I NSGCT is an option at specialized centers; identifies occult nodal disease and avoids chemotherapy in those without nodal involvement; requires robotic or open expertise to preserve ejaculatory function.

Stage II–IV: BEP Chemotherapy

Bleomycin + etoposide + cisplatin (BEP) is the backbone of curative therapy for metastatic GCT — among the most impactful therapeutic advances in oncologic history. The regimen was developed at Indiana University by Einhorn and Donohue in the late 1970s and transformed testicular cancer from a frequently lethal disease into one cured in the majority of cases even at stage IV.

• Good-risk metastatic GCT: 3 cycles of BEP (bleomycin day 1, 8, 15; etoposide 100 mg/m² days 1–5; cisplatin 20 mg/m² days 1–5; 21-day cycle). Alternatively, 4 cycles of EP (etoposide + cisplatin, omitting bleomycin) in patients at high risk for bleomycin pulmonary toxicity. Cure rate approximately 92%.
• Intermediate- and poor-risk metastatic GCT: 4 cycles of BEP. Ongoing trials (TIGER trial) evaluate whether high-dose chemotherapy with autologous stem cell transplant (HDCT/ASCT) improves outcomes vs standard BEP in poor-risk patients.
• Post-chemotherapy RPLND: For NSGCT patients with residual retroperitoneal masses after chemotherapy, surgical resection is standard — residual masses contain necrosis/fibrosis (~40%), mature teratoma (~40%), or viable GCT (~20%). Viable tumor requires 2 additional cycles of chemotherapy. Growing teratoma syndrome (enlarging retroperitoneal mass with normalizing markers) requires urgent surgery.
• Post-chemotherapy seminoma residual mass: FDG-PET is used to assess residual masses ≥3 cm at ≥6 weeks post-chemotherapy. PET-negative masses are observed; PET-positive masses require resection or biopsy.

Salvage Chemotherapy

For patients who relapse after first-line BEP, salvage options include conventional-dose VIP (etoposide + ifosfamide + cisplatin) or TIP (paclitaxel + ifosfamide + cisplatin), or high-dose chemotherapy with autologous stem cell transplant (HDCT/ASCT). HDCT with carboplatin + etoposide ± ifosfamide remains the preferred salvage approach at expert centers for cisplatin-sensitive relapse. Late relapse (>2 years after complete remission) carries worse prognosis and requires surgical resection of all accessible disease before chemotherapy.

Back to Table of Contents

9. Survivorship and Late Effects

Because testicular cancer strikes men in their reproductive prime and is cured in the vast majority, survivorship considerations are critically important. Most men will live decades beyond their diagnosis and must navigate long-term treatment-related morbidity.

• Fertility: Spermatogenesis may be impaired by the underlying disease, by orchiopexy, or by chemotherapy (cisplatin is gonadotoxic; effects are dose- and age-dependent). Sperm banking before any gonadotoxic treatment is strongly recommended and should be offered before orchiectomy when feasible. Approximately 50–70% of men treated with chemotherapy recover fertility within 2–5 years, but recovery is not guaranteed.
• Bleomycin pulmonary toxicity: Cumulative dose-dependent pulmonary fibrosis occurs in approximately 5–10% of patients; fatal in <1%. Risk is amplified by high inspired oxygen concentrations (anesthetic precautions required), renal insufficiency, and advanced age. Pulmonary function tests are monitored during BEP treatment.
• Cisplatin nephrotoxicity and peripheral neuropathy: Cisplatin-induced peripheral neuropathy (sensory, predominantly small-fiber) affects 20–40% of GCT survivors; severity is dose-related and may be permanent. Cisplatin causes cumulative nephrotoxicity and is associated with persistent hypomagnesemia requiring supplementation.
• Cardiovascular disease: GCT survivors treated with cisplatin-based chemotherapy have significantly elevated long-term cardiovascular risk — 2- to 3-fold increased rates of coronary artery disease, hypertension, dyslipidemia, and metabolic syndrome, particularly in the 5–20 year follow-up period. Mechanism involves cisplatin-associated endothelial dysfunction and accelerated atherosclerosis.
• Secondary malignancies: Radiation-associated secondary solid tumors (stomach, bladder, rectal cancer) are a late concern with prior retroperitoneal RT; etoposide is associated with therapy-related acute myeloid leukemia (t-AML) at cumulative doses >2,000 mg/m² (standard BEP dosing is well below this threshold in most patients).
• Psychological impact: Testicular cancer diagnosis in young men — a period of identity formation, career development, and relationship building — carries substantial psychological burden. Anxiety, depression, body image concerns related to orchiectomy, and sexual dysfunction are common; psycho-oncology referral is underutilized in practice.
• Hypogonadism: Approximately 15–25% of GCT survivors develop hypogonadism (low serum testosterone), particularly after bilateral orchiectomy or chemotherapy; testosterone replacement therapy is indicated for symptomatic hypogonadism.

Back to Table of Contents

10. Recent Research

Despite the already high cure rates, active research areas in testicular GCT focus on reducing treatment burden for good-risk patients, improving outcomes for poor-risk disease, and addressing survivorship toxicity.

• De-escalation in good-risk seminoma: Single-dose carboplatin has become increasingly favored over RT for stage I seminoma, and trials are exploring whether single-dose carboplatin AUC 10 (higher intensity) could further reduce relapse rates in high-risk stage I disease while preserving the toxicity advantage over radiation.
• HDCT as first-line for poor-risk NSGCT (TIGER trial): The TIGER trial compared 4 cycles of BEP versus high-dose chemotherapy with peripheral blood stem cell transplant as first-line therapy in poor-risk GCT. Results have been awaited to determine whether intensification upfront improves outcomes in this historically difficult-to-cure population.
• Robotic RPLND: Minimally invasive robotic retroperitoneal lymph node dissection has been validated in prospective series, demonstrating equivalent oncologic outcomes to open RPLND with shorter hospital stays and faster return to work. Adoption is growing at specialized centers.
• Checkpoint inhibitors in platinum-refractory GCT: Multiple-line GCT relapsing after HDCT has essentially no standard curative option. PD-1/PD-L1 inhibitors have shown modest activity in unselected GCT (ORR ~10–15%), but GCTs harboring microsatellite instability-high (MSI-H) or high tumor mutational burden (TMB-H) may respond more robustly. Clinical trials combining immunotherapy with chemotherapy or targeted agents are ongoing.
• Molecular predictors of relapse: GCNIS-derived miRNAs (particularly miR-371a-3p) are being validated as highly sensitive and specific serum biomarkers for active GCT, potentially supplementing or replacing traditional AFP/βhCG/LDH in situations where standard markers are normal (pure seminoma, mature teratoma).
• IGCCCG 2022 update: A landmark pooled reanalysis of 10,000 patients updated the IGCCCG system, confirming the three-group classification and validating clinical variables (LDH, βhCG, AFP, primary site, non-pulmonary visceral metastases) that stratify outcomes within the poor-risk group, potentially informing future biomarker-driven adaptive therapy.

Back to Table of Contents

Key Research Papers

1. Einhorn LH, Donohue J. Cis-diamminedichloride platinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977;87(3):293–298. PMID: 406401 | DOI: 10.7326/0003-4819-87-3-293
2. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15(2):594–603. PMID: 9053482 | DOI: 10.1200/JCO.1997.15.2.594
3. Oliver RT, Mason MD, Mead GM, et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet. 2005;366(9482):293–300. PMID: 16039331 | DOI: 10.1016/S0140-6736(05)66984-X
4. Tandstad T, Smaaland R, Solberg A, et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian Testicular Cancer Study Group. J Clin Oncol. 2011;29(6):719–725. PMID: 21205756 | DOI: 10.1200/JCO.2010.30.1044
5. Albers P, Albrecht W, Algaba F, et al. EAU Guidelines on Testicular Cancer. Eur Urol. 2011;60(2):304–319. PMID: 21632173 | DOI: 10.1016/j.eururo.2011.05.038
6. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med. 1987;316(23):1435–1440. PMID: 2437455 | DOI: 10.1056/NEJM198706043162301
7. Kollmannsberger C, Tandstad T, Bedard PL, et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol. 2015;33(1):51–57. PMID: 25348003 | DOI: 10.1200/JCO.2014.56.2116
8. Haugnes HS, Bosl GJ, Boer H, et al. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol. 2012;30(30):3752–3763. PMID: 23008318 | DOI: 10.1200/JCO.2012.43.4431
9. Looijenga LH, Stoop H, Biermann K. Testicular cancer: biology and biomarkers. Virchows Arch. 2019;474(4):407–420. PMID: 30868247 | DOI: 10.1007/s00428-018-2486-0
10. Oing C, Ruf C, Bokemeyer C. Testicular germ cell tumors: updates on biology and therapy. Curr Opin Oncol. 2017;29(3):155–161. PMID: 28375986 | DOI: 10.1097/CCO.0000000000000371
11. Nicolai N, Necchi A. Combination chemotherapy and targeted therapy in metastatic germ cell tumors. Expert Opin Pharmacother. 2018;19(8):823–833. PMID: 29715060 | DOI: 10.1080/14656566.2018.1467574
12. Gilligan T, Lin DW, Aggarwal R, et al. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(12):1529–1554. PMID: 31805526 | DOI: 10.6004/jnccn.2019.0058

Back to Table of Contents

PubMed Topic Searches

1. Testicular cancer treatment
2. Seminoma surveillance management
3. NSGCT BEP chemotherapy
4. GCT fertility preservation
5. Testicular cancer cryptorchidism risk
6. Retroperitoneal lymph node dissection
7. IGCCCG germ cell tumor prognosis
8. Testicular cancer late effects cisplatin
9. Testicular tumor markers AFP hCG
10. HDCT ASCT salvage germ cell tumor
11. miR-371a GCT biomarker
12. Testicular cancer cardiovascular survivors

Back to Table of Contents

Connections

• Cancer Overview
• Prostate Cancer
• Metastatic Cancers
• Lung Cancer
• Hypogonadism
• Brain Cancer
• Vitamin D3
• Zinc

Back to Table of Contents

Featured Videos